Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678830 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
A Phase 2 study of Coronavirus Disease 2019, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT04678830 is a Phase 2 study of Coronavirus Disease 2019 that has completed, run by CytoDyn. The registered enrollment target is 56 participants, below the 459-participant average among 4 other Coronavirus Disease 2019 trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04678830, a Phase 2 study of Coronavirus Disease 2019, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (\> 12 weeks) of COVID-19.
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Leronlimab (700mg)
Study Locations (2)
Florida
- Arthritis & Rheumatic Disease Specialties - Aventura
Georgia
- Center for Advanced Research & Education (CARE) - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04678830
The ClinicalTrials.gov registry entry for NCT04678830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 459-participant average among 4 other Coronavirus Disease 2019 trials with a reported enrollment target (88% lower). The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronavirus Disease 2019 appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.
NCT04678830 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04678830 about?
NCT04678830 is a clinical study titled "Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19". The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (\> 12 weeks) of COVID-19.
What is the current status of trial NCT04678830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-03-01. Estimated completion is 2021-07-08.
What conditions does trial NCT04678830 study?
This clinical trial studies the following conditions: Coronavirus Disease 2019.
What interventions are being tested in trial NCT04678830?
The interventions under investigation include: Placebos (DRUG), Leronlimab (700mg) (DRUG).
Who is sponsoring clinical trial NCT04678830?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04678830 being conducted?
This trial has 2 study locations across Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus Disease 2019
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
COMPLETED · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
ACTIVE NOT RECRUITING
-
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.